Abstract 1975P
Background
Journal of Global Oncology (ASCO) published that the new patients per oncologist ratio ranges from 30 to 15,000 across different countries, with only 24% countries having the ratio below 150. This can result in a low quality of care for many cancer patients. Also, South Asian Journal of Cancer published that 85% cancer patients prefer to know the possible treatment options. ZIOPAR provides Artificial Intelligence-based assessment reports free of cost to cancer patients to guide them on possible treatment options, covering both medical as well as complementary approaches.
Methods
Our team has developed an Artificial Intelligence-based program based on standard protocols, guidelines and research by ESMO, NCCN, ASCO, SIO, others. Cancer patients are required to provide below six basic inputs that determine the output of the report:
► Cancer type / organ site.
► Cancer stage.
► Prior treatment taken (surgery, chemotherapy, radiation therapy).
► Performance status (based on activities that can be performed).
► Symptoms and side-effects (eg, pain, nausea, anxiety).
► Other medical conditions (eg, thyroid, diabetes, liver cirrhosis)
Based on these inputs, a report is generated that outlines medical treatment options, diagnostic tests required, and complementary treatment approaches (including guidelines on nutrition, fitness, stress-management, symptom management). Operationally, ZIOPAR captures patient data through an online form, which is transferred to an application that uses Artificial Intelligence to send optimized reports for each patient individually based on specific inputs shared by the patient. The report is shared through email in pdf form to enhance security.
Results
ZIOPAR has already benefitted 21,000+ cancer patients and caregivers across 16 countries through its detailed Artificial Intelligence-based preliminary assessment report.
Conclusions
ZIOPAR can help millions of cancer patients by providing them an integrative oncology preliminary assessment report containing crucial information to help them decide their treatment option, covering both medical as well as complementary approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ZenHeal Wellness Private Limited (ZenOnco.io).
Funding
Has not received any funding.
Disclosure
K. Shah: Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: ZenHeal Wellness Private Limited (ZenOnco.io); Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Nityanootan Foundation (Love Heals Cancer). D. Parmar: Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: ZenHeal Wellness Private Limited (ZenOnco.io); Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Nityanootan Foundation (Love Heals Cancer).